NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update
NRx Pharmaceuticals, Inc. today announced that it had a meeting and a written response from the Food and Drug Administration (FDA) last week regarding its lead compound, NRX-101.
NRx Pharmaceuticals, Inc. today announced it has initiated a Phase 3 registrational trial targeting suicidal bipolar depression with suicidality and has signed the first clinical site contract.
NRx Pharmaceuticals today announced the appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP as Senior Vice President, Clinical Development and Medical Affairs. She will lead the Company’s clinical development program and provide medical oversight across all indications. Dr. Carretta will report to the Chief Executive Officer and Director.
NRx Pharmaceuticals today announced it received written notice on December 1, 2022 from The Nasdaq Stock Market informing NRx Pharmaceuticals that it has regained compliance with the minimum bid price requirement under the Nasdaq Listing Rule 5450(a)(1) (which requires the Company to maintain a minimum closing bid price of $1.00 per share) and the matter is now closed.
NRx Pharmaceuticals, Inc. today announced its financial results for the third quarter of 2022 and provided a business and clinical update.
Relief Therapeutics Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) (“Relief”), and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) (“NRx Pharmaceuticals”), today announced that they have entered into definitive settlement agreements to resolve their pending litigation.
NRx Pharmaceuticals, Inc. today announced the release of the first batches manufactured in the U.S. of NRX-101, its Phase 3-ready investigational drug, targeting suicidal bipolar depression and with future study plans for post-traumatic stress disorder (PTSD).
NRx Pharmaceuticals, Inc. today announced that it has obtained approximately $11 million in unsecured debt financing (the “Note”) from Streeterville Capital, LLC, a Utah limited liability company.